{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:48:51Z","timestamp":1790275731719,"version":"4.1.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T00:00:00Z","timestamp":1516924800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00032","type":"journal-article","created":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T04:24:42Z","timestamp":1516940682000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Protective Mechanism of Hydrogen Sulfide against Chemotherapy-Induced Cardiotoxicity"],"prefix":"10.3389","volume":"9","author":[{"given":"Shuxu","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,1,26]]},"reference":[{"key":"B1","first-page":"586","article-title":"Chemotherapy-induced cardiovascular toxicity: beyond anthracyclines","volume":"80","author":"Ai","year":"2014","journal-title":"Minerva Anestesiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.2174\/0929867321666140706142930","article-title":"Hydrogen sulfide and endothelial dysfunction: relationship with nitric oxide","volume":"21","author":"Altaany","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"795602","DOI":"10.1155\/2015\/795602","article-title":"Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress","volume":"2015","author":"Angsutararux","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.pharep.2015.01.005","article-title":"Hydrogen sulfide in pharmacology and medicine\u2013An update","volume":"67","author":"Be\u0142towski","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6549625","DOI":"10.1155\/2016\/6549625","article-title":"Hydrogen sulfide: biogenesis, physiology, and pathology","volume":"2016","author":"Bian","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3389\/fphar.2016.00385","article-title":"The role of hydrogen sulfide in renal system","volume":"7","author":"Cao","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1021\/acs.jmedchem.6b00184","article-title":"H2S-donating doxorubicins may overcome cardiotoxicity and multidrug resistance","volume":"59","author":"Chegaev","year":"2016","journal-title":"J. Med. Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"84338","DOI":"10.18632\/oncotarget.12609","article-title":"H2S-releasing nanoemulsions: a new formulation to inhibit tumor cells proliferation and improve tissue repair","volume":"7","author":"Ciocci","year":"2016","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00204-016-1759-y","article-title":"Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone","volume":"90","author":"Damiani","year":"2016","journal-title":"Arch. Toxicol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.lfs.2013.10.013","article-title":"The role of autophagy in doxorubicin-induced cardiotoxicity","volume":"93","author":"Dirks-Naylor","year":"2013","journal-title":"Life Sci."},{"key":"B13","first-page":"3443","article-title":"Adequate hydrogen sulfide, healthy circulation","volume":"124","author":"Du","year":"2011","journal-title":"Chin. Med. J."},{"key":"B14","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.3760\/cma.j.issn.0366-6999.20133106","article-title":"Immune regulation of hydrogen sulfide in children with acute lymphoblastic leukemia","volume":"127","author":"Du","year":"2014","journal-title":"Chin. Med. J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.tox.2016.10.001","article-title":"An integrative view of cisplatin-induced renal and cardiac toxicities: molecular mechanisms, current treatment challenges and potential protective measures","volume":"371","author":"Dugbartey","year":"2016","journal-title":"Toxicology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s11906-010-0146-y","article-title":"Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage","volume":"12","author":"Geisberg","year":"2010","journal-title":"Curr. Hypertens. Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-017-0601-x","article-title":"Cancer as a risk factor for cardiovascular disease","volume":"19","author":"Giza","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/jpi.12176","article-title":"Mitochondrial catastrophe during doxorubicin-induced cardiotoxicity: a review of the protective role of melatonin","volume":"57","author":"Govender","year":"2014","journal-title":"J. Pineal Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3892\/ijmm.2013.1246","article-title":"Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibition of the p38 MAPK pathway in H9c2 cells","volume":"31","author":"Guo","year":"","journal-title":"Int. J. Mol. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1159\/000356602","article-title":"Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK\/NF\u03baB pathway in H9c2 cardiac cells","volume":"32","author":"Guo","year":"","journal-title":"Cell. Physiol. Biochem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3892\/mmr.2013.1554","article-title":"Activation of the p38 MAPK\/NF-\u03baB pathway contributes to doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells","volume":"8","author":"Guo","year":"","journal-title":"Mol. Med. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3389\/fonc.2014.00346","article-title":"Cardiovascular toxicities from systemic breast cancer therapy","volume":"4","author":"Guo","year":"2014","journal-title":"Front. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular toxicities of cancer therapies: the old and the new\u2013an evolving avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s10741-015-9502-y","article-title":"Chemotherapy-induced cardiomyopathy","volume":"20","author":"Higgins","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/03602532.2017.1316285","article-title":"The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs","volume":"49","author":"Hrynchak","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fphar.2017.00128","article-title":"Hydrogen sulfide inhibits high-salt diet-induced myocardial oxidative stress and myocardial hypertrophy in Dahl rats","volume":"8","author":"Huang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/bcp.13120","article-title":"Prevention of cardiotoxicity among survivors of childhood cancer","volume":"83","author":"Hutchins","year":"2017","journal-title":"Br. J. Clin. Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1139\/cjpp-2012-0315","article-title":"Garlic and cardioprotection: insights into the molecular mechanisms","volume":"91","author":"Khatua","year":"2013","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00726-010-0510-x","article-title":"Hydrogen sulfide: its production, release and functions","volume":"41","author":"Kimura","year":"2011","journal-title":"Amino Acids"},{"key":"B30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2183\/pjab.91.131","article-title":"Hydrogen sulfide and polysulfides as signaling molecules","volume":"91","author":"Kimura","year":"2015","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11912-016-0521-1","article-title":"Fluoropyrimidine-induced cardiotoxicity: manifestations, mechanisms, and management","volume":"18","author":"Layoun","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-oncology: an update on cardiotoxicity of cancer-related treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/pbc.24597","article-title":"Cardiotoxicity in childhood cancer survivors: a problem with long-term consequences in need of early detection and prevention","volume":"60","author":"Lipshultz","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1146\/annurev-med-070213-054849","article-title":"Cardiovascular disease in adult survivors of childhood cancer","volume":"66","author":"Lipshultz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3892\/mmr.2015.4544","article-title":"Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibiting the expression of peroxiredoxin III in H9c2 cells","volume":"13","author":"Liu","year":"","journal-title":"Mol. Med. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"6841","DOI":"10.3892\/mmr.2015.4234","article-title":"Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibiting reactive oxygen species-activated extracellular signal-regulated kinase 1\/2 in H9c2 cardiac myocytes","volume":"12","author":"Liu","year":"","journal-title":"Mol. Med. Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3892\/ijmm.2016.2563","article-title":"Hydrogen sulfide protects H9c2 cardiac cells against doxorubicin-induced cytotoxicity through the PI3K\/Akt\/FoxO3a pathway","volume":"37","author":"Liu","year":"","journal-title":"Int. J. Mol. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5197","DOI":"10.3892\/mmr.2015.4020","article-title":"Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibiting calreticulin expression in H9c2 cells","volume":"12","author":"Liu","year":"","journal-title":"Mol. Med. Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.rec.2016.12.041","article-title":"Cardio-onco-hematology in clinical practice. Position paper and recommendations","volume":"70","author":"Lopez-Fernandez","year":"2017","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.2459\/JCM.0000000000000376","article-title":"Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy","volume":"17","author":"Madeddu","year":"2016","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cppeds.2016.04.003","article-title":"Progress and prospects in pediatric leukemia","volume":"46","author":"Madhusoodhan","year":"2016","journal-title":"Curr. Probl. Pediatr. Adolesc. Health Care"},{"key":"B42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc. Drugs Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1517\/14740338.2011.589834","article-title":"Anthracycline cardiotoxicity","volume":"11","author":"Menna","year":"2012","journal-title":"Expert Opin. Drug Saf"},{"key":"B44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2350\/13-04-1324-CR.1","article-title":"Cyclophosphamide-associated cardiotoxicity in a child after stem cell transplantation for \u03b2-thalassemia major: case report and review of the literature","volume":"17","author":"Meserve","year":"2014","journal-title":"Pediatr. Dev. Pathol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijcha.2015.11.004","article-title":"Doxorubicin induced heart failure: phenotype and molecular mechanisms","volume":"10","author":"Mitry","year":"2016","journal-title":"Int. J. Cardiol. Heart Vasc"},{"key":"B46","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1586\/14779072.2015.1032940","article-title":"Cardio-oncology Part I: chemotherapy and cardiovascular toxicity","volume":"13","author":"O'Hare","year":"2015","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1152\/physiol.00024.2015","article-title":"The role of hydrogen sulfide in evolution and the evolution of hydrogen sulfide in metabolism and signaling","volume":"31","author":"Olson","year":"2016","journal-title":"Physiology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10549-011-1693-x","article-title":"Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy","volume":"133","author":"Panis","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"B49","doi-asserted-by":"publisher","first-page":"9049782","DOI":"10.1155\/2016\/9049782","article-title":"Physiological importance of hydrogen sulfide: emerging potent neuroprotector and neuromodulator","volume":"2016","author":"Panthi","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/2050-6511-15-47","article-title":"A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"15","author":"Polk","year":"2014","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pharmthera.2015.04.004","article-title":"Hydrogen sulfide and cardioprotection\u2013Mechanistic insights and clinical translatability","volume":"152","author":"Salloum","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3238\/arztebl.2014.0161","article-title":"Cardiotoxicity and oncological treatments","volume":"111","author":"Schlitt","year":"2014","journal-title":"Dtsch. Arztebl. Int."},{"key":"B53","doi-asserted-by":"publisher","first-page":"925167","DOI":"10.1155\/2015\/925167","article-title":"The cardioprotective effects of hydrogen sulfide in heart diseases: from molecular mechanisms to therapeutic potential","volume":"2015","author":"Shen","year":"2015","journal-title":"Oxid. Med. Cell. Longev"},{"key":"B54","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1253\/circj.CJ-08-0636","article-title":"Hydrogen sulfide regulates cardiac function and structure in adriamycin-induced cardiomyopathy","volume":"73","author":"Su","year":"2009","journal-title":"Circ. J"},{"key":"B55","doi-asserted-by":"publisher","first-page":"6093783","DOI":"10.1155\/2016\/6093783","article-title":"Myricitrin protects against doxorubicin-induced cardiotoxicity by counteracting oxidative stress and inhibiting mitochondrial apoptosis via ERK\/P53 pathway","volume":"2016","author":"Sun","year":"2016","journal-title":"Evid. Based Complement. Alternat. Med"},{"key":"B56","first-page":"3816","article-title":"Hydrogen sulfide and vascular relaxation","volume":"124","author":"Sun","year":"2011","journal-title":"Chin. Med. J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nrd.2015.1","article-title":"Gasotransmitters in cancer: from pathophysiology to experimental therapy","volume":"15","author":"Szabo","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"B58","doi-asserted-by":"publisher","first-page":"528","DOI":"10.2741\/4407","article-title":"Nature creates, adapts, protects and sustains life using hydrogen sulfide","volume":"21","author":"Tabibzadeh","year":"2016","journal-title":"Front. Biosci"},{"key":"B59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/157016106775203144","article-title":"Hydrogen sulfide as a new endogenous gaseous transmitter in the cardiovascular system","volume":"4","author":"Tang","year":"2006","journal-title":"Curr. Vasc. Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1002\/jcp.24039","article-title":"Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity","volume":"227","author":"Tesei","year":"2012","journal-title":"J Cell Physiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2016.6930","article-title":"From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: a translational overview","author":"Tocchetti","year":"2017","journal-title":"Antioxid Redox Signal."},{"key":"B62","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1161\/CIRCGENETICS.113.000381","article-title":"Induction of microRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in mice","volume":"7","author":"Toldo","year":"2014","journal-title":"Circ. Cardiovasc. Genet"},{"key":"B63","doi-asserted-by":"publisher","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","article-title":"Drug-induced mitochondrial dysfunction and cardiotoxicity","volume":"309","author":"Varga","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrd4433","article-title":"Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter","volume":"14","author":"Wallace","year":"2015","journal-title":"Nat. Rev. Drug Discov"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2017.7068","article-title":"Hydrogen sulfide-releasing therapeutics: translation to the clinic","author":"Wallace","year":"2017","journal-title":"Antioxid Redox Signal."},{"key":"B66","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11010-011-1194-6","article-title":"Hydrogen sulfide protects H9c2 cells against doxorubicin-induced cardiotoxicity through inhibition of endoplasmic reticulum stress","volume":"363","author":"Wang","year":"2012","journal-title":"Mol. Cell. Biochem."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e2339","DOI":"10.1038\/cddis.2016.209","article-title":"Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity","volume":"7","author":"Wu","year":"2016","journal-title":"Cell Death Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.bbrc.2015.02.017","article-title":"Hydrogen sulfide protects against myocardial ischemia and reperfusion injury by activating AMP-activated protein kinase to restore autophagic flux","volume":"458","author":"Xie","year":"2015","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"B69","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-3-319-18144-8_4","article-title":"H2S and blood vessels: an overview","volume":"230","author":"Yang","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"95425","DOI":"10.18632\/oncotarget.20729","article-title":"Gas signaling molecule hydrogen sulfide attenuates doxorubicin-induced dilated cardiomyopathy","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e26441","DOI":"10.1371\/journal.pone.0026441","article-title":"S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling","volume":"6","author":"Zhang","year":"2011","journal-title":"PLoS ONE"},{"key":"B73","doi-asserted-by":"publisher","first-page":"44735","DOI":"10.1038\/srep44735","article-title":"Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep"},{"key":"B74","doi-asserted-by":"publisher","first-page":"11788","DOI":"10.1039\/C4CC00968A","article-title":"Hydrogen sulfide (H2S) releasing agents: chemistry and biological applications","volume":"50","author":"Zhao","year":"2014","journal-title":"Chem. Commun."},{"key":"B75","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/978-3-319-18144-8_18","article-title":"Medicinal chemistry: insights into the development of novel H2S donors","volume":"230","author":"Zhao","year":"2015","journal-title":"Handb. Exp. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2018.00032\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T19:11:40Z","timestamp":1719774700000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2018.00032\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,26]]},"references-count":75,"alternative-id":["10.3389\/fphar.2018.00032"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00032","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,26]]},"article-number":"32"}}